Skip to main content

Errata - English

PDF CSV May 16, 2022 through May 16, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Sort ascending Description
CETYL ALCOHOL IMPURITIES/Limit of Related Fatty Alcohols USP39–NF34 7239 1-Jun-2016 USP40–NF35 USP40–NF35 Line 1 of Sample solution: Change
1 mg/mL of Cetyl Alcohol in ethanol
to:
Prepare 1.0 mg/mL of Cetyl Alcohol in ethanol, and heat the solution in a sealed container in a 50° water bath until cetyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well.
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER IMPURITIES/Limit of Methacrylic Acid and Ethyl Acrylate First Supplement to USP39–NF34 Online 1-Apr-2016 USP40–NF35 USP40–NF35 Line 5 of Standard solution: Change
Mix 10.0 mL of this solution
to:
Mix 5.0 mL of this solution
AND
Line 7 of Standard solution: Change
about 0.67 µg/mL
to:
about 0.5 µg/mL
Line 4 of Sample solution: Change
10.0 mL of this solution
to:… Read More
LORAZEPAM INJECTION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP39–NF34 4620 1-Jun-2016 USP40–NF35 USP40–NF35 Line 3 of Lorazepam Related Compound B RS: Change
C13H9ClNO
to:
C13H9Cl2NO
RANITIDINE ORAL SOLUTION USP Reference standards <11> USP39–NF34 5671 1-Jun-2016 USP40–NF35 USP40–NF35 Line 2 of USP Ranitidine Related Compound C RS: Change
N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine.
to:
N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More
<1132> RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS 4. HCP IMMUNOASSAY METHOD VALIDATION/4.3 Sample Linearity/Table 4 Second Supplement to USP38–NF33 7647 1-Apr-2016 USP40–NF35 USP40–NF35 Product column: Change
10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16
to:
10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625
AND
Sample 1/HCP ratio column: Change
4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6
to:
4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6
AND… Read More
MYRISTYL ALCOHOL ASSAY/Procedure USP39–NF34 7413 1-Jun-2016 USP40–NF35 USP40–NF35 Line 1 of Standard solution: Change
Prepare 1.0 mg/mL of USP Myristyl Alcohol RS in Internal standard solution, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well.
to… Read More
DIGOXIN IMPURITIES/Related Glycosides/System suitability Interim Revision Announcement (Official November 01, 2015) Online 1-Apr-2016 USP40–NF35 USP40–NF35 Line 2: Change
Sample: System suitability solution
to:
Samples: System suitability solution and Standard solution
AND
Line 2 of Suitability requirements: Change
Resolution: NLT 1.5 between the digoxin and lanatoside C peaks
Relative… Read More
LORAZEPAM ORAL CONCENTRATE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP39–NF34 4621 1-Jun-2016 USP40–NF35 USP40–NF35 Line 3 of Lorazepam Related Compound B RS: Change
C13H9ClNO
to:
C13H9Cl2NO
RANITIDINE TABLETS USP Reference standards <11> USP39–NF34 5672 1-Jun-2016 USP40–NF35 USP40–NF35 Line 2 of USP Ranitidine Related Compound C RS: Change
N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine.
to:
N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More
<661.1> PLASTIC MATERIALS OF CONSTRUCTION SPECIFICATIONS/Polyethylene/Extractable Metals USP39–NF34 493 1-Apr-2016 USP40–NF35 USP40–NF35 Line 1 of Zirconium: Change
1 µg/g.
to:
0.1 µg/g.
OLEYL ALCOHOL ASSAY/Procedure USP39–NF34 7424 1-Jun-2016 USP40–NF35 USP40–NF35 Line 1 of Standard solution: Change
Prepare 1.0 mg/mL of USP Oleyl Alcohol RS in Internal standard solution, and heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well.
to:
1.… Read More
MEMANTINE HYDROCHLORIDE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2015) Online 1-Apr-2016 USP40–NF35 USP40–NF35 Line 3 of Analysis: Change
of USP Memantine Related Compound E RS or
to:
of memantine related compound E or
AND
In the variable definition list: Change
rU = peak response of USP Memantine Related Compound E RS or any individual degradation product from… Read More
LORAZEPAM TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards RS <11> USP39–NF34 4622 1-Jun-2016 USP40–NF35 USP40–NF35 Line 3 of USP Lorazepam Related Compound B RS: Change
C13H9ClNO
to:
C13H9Cl2NO
RANITIDINE IN SODIUM CHLORIDE INJECTION USP Reference standards <11> USP39–NF34 5673 1-Jun-2016 USP40–NF35 USP40–NF35 Line 2 of USP Ranitidine Related Compound C RS: Change
N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine.
to:
N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More
<661.1> PLASTIC MATERIALS OF CONSTRUCTION SPECIFICATIONS/Polyethylene Terephthalate and Polyethylene Terephthalate G/Extractable Metals USP39–NF34 493 1-Apr-2016 USP40–NF35 USP40–NF35 Line 1 of Titanium: Change
0.1 µg/g.
to:
1 µg/g.
SODIUM CETOSTEARYL SULFATE IMPURITIES/Limit of Sodium Chloride and Sodium Sulfate/Sodium sulfate/Titrimetric system USP39–NF34 7518 1-Jun-2016 USP40–NF35 USP40–NF35 Line 1 of Endpoint detection: Change
Potentiometric
to:
Visual
<1724> SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS IN VITRO PERFORMANCE TESTS USP39–NF34 1869 1-Jun-2016 USP40–NF35 USP40–NF35 Line 7 of Application of Drug Release: Change
The individual amounts of drug released from R is plotted versus time,
to:
The individual amounts of drug released from R are plotted versus the square root of time,
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711> USP39–NF34 4766 1-Jun-2016 USP40–NF35 USP40–NF35 Line 3 of Test 3: Change
Medium, Apparatus 1, Apparatus 2, and Analysis:
to:
Medium, Apparatus 1, and Apparatus 2:
SAMARIUM Sm 153 LEXIDRONAM INJECTION Other requirements USP39–NF34 5791 1-Jun-2016 USP40–NF35 USP40–NF35 Line 1: Change
Injections and Implanted Drug Products <1>; not subject to Container Content.
to:
Meets the requirements of Injections and Implanted Drug Products <1>; not subject to Container content.
<661.1> PLASTIC MATERIALS OF CONSTRUCTION TEST METHODS/Extractions/Table 3 USP39–NF34 493 1-Apr-2016 USP40–NF35 USP40–NF35 Column 4 of S3 row: Change
Extractable metals: Al, Sb, As, Ba, Cd, Co, Ge, Hg, Mn, Ni, Pb, Ti, V, and Zn
to:
Extractable metals: Al, As, Ba, Cd, Co, Hg, Mn, Ni, Pb, Ti, V, and Zn
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS 5. FACILITIES AND ENGINEERING CONTROLS/5.3 Compounding First Supplement to USP39–NF34 7721 1-Jun-2016 USP40–NF35 USP40–NF35 First bullet in second paragraph: Change
• Be externally vented through high-efficiency particulate air (HEPA) filtration
to:
• Be externally vented
REAGENTS, INDICATORS AND SOLUTIONS REAGENTS/6. General Tests for Reagents/6.2 Amino Nitrogen Test in Reagents USP39–NF34 2080 1-Jun-2016 USP40–NF35 USP40–NF35 In the numerator of the equation: Change
2.8
to:
14
AND
Add
× f
AND
Line 10: Change
where %LOD is the percentage of loss on drying.
to:
where f is the correction factor obtained in the standardization of 0.2 N sodium hydroxide and %LOD is the… Read More
MYCOPHENOLATE SODIUM ASSAY/Procedure USP39–NF34 4965 1-Jun-2016 USP40–NF35 USP40–NF35 Line 3: Change
Solvent A
to:
Solution A
AND
Line 5: Change
Solvent B
to:
Solution B
TETRACYCLINE HYDROCHLORIDE CAPSULES ASSAY/Procedure USP39–NF34 6082 1-Jun-2016 USP40–NF35 USP40–NF35 Line 6 of Sample solution: Change
dilute with Diluent to volume.
to:
dilute with Solution A to volume.
<661.1> PLASTIC MATERIALS OF CONSTRUCTION TEST METHODS/Extractions/Table 3 USP39–NF34 493 1-Apr-2016 USP40–NF35 USP40–NF35 Line 1 of footnote b: Change
For nonplasticized polyethylene only.
to:
For polyethylene only.
ALPRAZOLAM EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711> USP39–NF34 2389 1-Jun-2016 USP40–NF35 USP40–NF35 Variable definition list of second equation in Test 2/Analysis: Change
VS = volume of the Sample solution withdrawn at each time point and replaced with Medium (mL)
to:
VS = volume of the Sample solution withdrawn at… Read More
PAROXETINE EXTENDED-RELEASE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> First Supplement to USP39–NF34 8121 1-Jun-2016 USP40–NF35 USP40–NF35 USP Paroxetine Related Compound B RS: Add
C19H21NO3 · HCl 347.84
IDARUBICIN HYDROCHLORIDE INJECTION SPECIFIC TESTS/Constituted Solution USP38–NF33 3834 1-Jun-2015 USP39–NF34 USP39–NF34 Delete the Constituted Solution test.
PHENYTOIN SODIUM USP Reference standards <11> USP37–NF32 4289 1-Apr-2015 USP39–NF34 USP39–NF34 Line 3 of USP Phenytoin Related Compound A RS: Change
C14H15NO2
to:
C14H13NO2
NIACIN IMPURITIES/Related Compounds First Supplement to USP38–NF33 7447 1-Jun-2015 USP39–NF34 USP39–NF34 Row 14 of Column 1 of Table 2: Change
Total impurities
to:
Total specified impurities
BISMUTH SUBCARBONATE IMPURITIES/Limit of Lead USP38–NF33 2449 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Acceptance criteria: Change
Meets the requirements
to:
NMT 0.002%
REAGENTS REAGENT SPECIFICATIONS/Ferric Sulfate USP38–NF33 1841 1-Jun-2015 USP39–NF34 USP39–NF34 Line 1: Change
[10028-22-5]
to:
[15244-10-7]
LEVETIRACETAM IMPURITIES/Organic Impurities USP38–NF33 4060 1-Jun-2015 USP39–NF34 USP39–NF34 Line 2 of Procedure 2: Change
Buffer, Solution A, Solution B, Mobile phase, System suitability solution, and Chromatographic system:
to:
Buffer, Solution A, Solution B, Mobile phase, System suitability solution, Chromatographic system, and System suitability… Read More
RIVASTIGMINE TARTRATE CAPSULES ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 4616 1-Apr-2015 USP39–NF34 USP39–NF34 Line 2 of USP Rivastigmine Related Compound A RS: Change
Di-p-toluoyl-D-(+)-tartaric acid monohydrate.
C20H20O9 404.37
to:
(+)-Di-(p-toluoyl)-D-tartaric acid.
C20H18O8 386.35
VERAPAMIL HYDROCHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 7 First Supplement to USP38–NF33 7478 1-Jun-2015 USP39–NF34 USP39–NF34 Line 6 of Analysis: Change
37 ± 0.5° at each time point.
to:
37 ± 0.5°.
AND
Line of 40 of Analysis:Delete the equation
Result5 = ({C5 × [V − (4 × Vs)]} + [(C4 + C3 + C2… Read More
CISATRACURIUM BESYLATE INJECTION ASSAY/Procedure USP38–NF33 2830 1-Apr-2015 USP39–NF34 USP39–NF34 Line 11 of Analysis: Change
CS = concentration of USP Cisatracurium Besylate RS in the Standard solution
to:
CS = concentration of USP Cisatracurium Besylate RS in the Standard solution (mg/mL)
ALUMINUM CHLOROHYDRATE CHEMICAL INFORMATION USP38–NF33 2130 1-Jun-2015 USP39–NF34 USP39–NF34 Line 8: Change
Dihydrate [12042-91-0].Anhydrous [1327-41-9].
to:
Dihydrate [12359-72-7].Anhydrous [12042-91-0].
LEVODOPA CAPSULES IMPURITIES/Organic Impurities USP38–NF33 4078 1-Jun-2015 USP39–NF34 USP39–NF34 Line 2 of Spray reagent: Change
(10 mg/mL)
to:
(100 mg/mL)
WITCH HAZEL Limit of tannins USP37–NF32 5177 1-Apr-2015 USP39–NF34 USP39–NF34 Line 3 of Chromatographic system: Change
5.0-mm × 15-cm
to:
4.6-mm × 15-cm
SODIUM CHLORIDE IMPURITIES/Limit of Phosphates Harmonization (Official December 01, 2015) Online 1-Jun-2015 USP39–NF34 USP39–NF34 Line 2 of Analysis: Change
add 4 mL of sulfomolybdic acid TS,
to:
add 4 mL of Sulfomolybdic acid solution,
CLARITHROMYCIN TABLETS IMPURITIES/Organic Impurities/Chromatographic system USP38–NF33 2850 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Column: Change
4.6-mm × 10-cm; 3-µm packing L1
to:
4.6-mm × 10-cm; 3.5-µm packing L1
AZATHIOPRINE ASSAY/Procedure USP38–NF33 2334 1-Jun-2015 USP39–NF34 USP39–NF34 Line 1 of Standard stock solution: Change
0.1 mg/mL of USP Azathioprine RS prepared as follows.
to:
0.5 mg/mL of USP Azathioprine RS prepared as follows.
METHYLPHENIDATE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 4345 1-Jun-2015 USP39–NF34 USP39–NF34 Line 3 of USP Methylphenidate Related Compound A RS: Change
255.75
to:
255.74
ASPARTAME ASSAY/Procedure USP37–NF32 5857 1-Apr-2015 USP39–NF34 USP39–NF34 Line 3 of Analysis: Change
crystal violet
to:
crystal violet TS
TELMISARTAN TABLETS ASSAY/Procedure Revision Bulletin (Official December 01, 2014) Online 1-Jun-2015 USP39–NF34 USP39–NF34 Line 2 of Standard solution: Change
of USP Telmisartan Related Compound A RS in Mobile phase.
to:
of USP Telmisartan Related Compound A RS in Mobile phase from the Standard stock solution.
COSYNTROPIN IDENTIFICATION/B. Amino Acid Analysis USP38–NF33 2958 1-Apr-2015 USP39–NF34 USP39–NF34 Line 8 of Sample hydrolysate preparation: Change
hydrochloride
to:
hydrochloric acid
BENZOYL PEROXIDE GEL IMPURITIES/Organic Impurities USP38–NF33 2399 1-Jun-2015 USP39–NF34 USP39–NF34 Line 18 of Standard solution D: Change
hydrous benzoyl peroxide (C14H10O4).
to:
anhydrous benzoyl peroxide (C14H10O4).
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP38–NF33 4348 1-Jun-2015 USP39–NF34 USP39–NF34 Line 3 of Apparatus 7: Change
coil sample holder (Figure 4d).
to:
spring sample holder (Figure 5d).
PURIFIED BENTONITE IDENTIFICATION/A. X-Ray Diffraction <941> USP37–NF32 5862 1-Apr-2015 USP39–NF34 USP39–NF34 Line 4 of Acceptance criteria: Change
from the pattern of Sample B is 1.492 and 1.504 Å.
to:
from the pattern of Sample B is between 1.492 and 1.504 Å.
TELMISARTAN TABLETS IDENTIFICATION/A. Ultraviolet Absorption <197U> Revision Bulletin (Official December 01, 2014) Online 1-Jun-2015 USP39–NF34 USP39–NF34 Line 3: Change
as obtained in the test for Dissolution.
to:
as obtained in the test for Dissolution, Test 1.